UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 940

Sortiert nach

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors

Clinical cancer research, 2021-09, Vol.27 (17), p.4685-4689

2021

Volltextzugriff (PDF)

Spontaneous Object Exploration in a Recessive Gene Knockout Model of Parkinson's Disease: Development and Progression of Object Recognition Memory Deficits in Male Pink1-/- Rats

Frontiers in behavioral neuroscience, 2022-12, Vol.16, p.951268-951268

2022

Volltextzugriff (PDF)

Effect of educational intervention on medication reconciliation practice of hospital pharmacists in a developing country – A non-randomised controlled trial

BMC medical education, 2023-11, Vol.23 (1), p.1-867, Article 867

2023

Volltextzugriff (PDF)

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data

Blood cancer journal (New York), 2022-04, Vol.12 (4), p.65-65, Article 65

2022

Volltextzugriff (PDF)

Traces and Memories of Slavery in the Atlantic World

1st edition., 2019

Volltextzugriff (PDF)

The On- and Off-Ramps of Oncology Accelerated Approval

The New England journal of medicine, 2022-10, Vol.387 (16), p.1439-1442

2022

Volltextzugriff (PDF)

The Many Faces of Slavery : New Perspectives on Slave Ownership and Experiences in the Americas

1, 2019

Volltextzugriff (PDF)

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical cancer research, 2022-07, Vol.28 (13), p.2733-2737

2022

Volltextzugriff (PDF)

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical cancer research, 2024-01, Vol.30 (2), p.269

2024

Volltextzugriff (PDF)

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

Clinical cancer research, 2023-11, Vol.29 (21), p.4326

2023

Volltextzugriff (PDF)

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical cancer research, 2023-03, Vol.29 (5), p.838-842

2023

Volltextzugriff (PDF)

Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges

Clinical cancer research, 2023-09, Vol.29 (18), p.3566

2023

Volltextzugriff (PDF)

Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials

The oncologist (Dayton, Ohio), 2024-04, Vol.29 (4), p.356-363

2024

Volltextzugriff (PDF)

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Clinical cancer research, 2023-10, Vol.29 (20), p.4027

2023

Volltextzugriff (PDF)

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Clinical cancer research, 2023-06, Vol.29 (11), p.2020-2024

2023

Volltextzugriff (PDF)

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical cancer research, 2022-12, Vol.28 (24), p.5244-5248

2022

Volltextzugriff (PDF)

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical cancer research, 2021-11, Vol.27 (21), p.5753-5756

2021

Volltextzugriff (PDF)

Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests

JAMA oncology, 2024-03, Vol.10 (3), p.380

2024

Volltextzugriff (PDF)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials

Blood advances, 2022-03, Vol.6 (6), p.1684-1691

2022

Volltextzugriff (PDF)

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

Cancer discovery, 2023-12, Vol.13 (12), p.2515

2023

Volltextzugriff (PDF)

FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity

Clinical lymphoma, myeloma and leukemia, 2023-06, Vol.23 (6), p.463-470.e1

2023

Volltextzugriff (PDF)

To Adjudicate or Not Adjudicate: That Is the Question

JACC CardioOncology, 2022-12, Vol.4 (5), p.657-659

2022

Volltextzugriff (PDF)

The Many Faces of Slavery

2019

Volltextzugriff (PDF)

Re-Imagining the Guyanas

2019

Volltextzugriff (PDF)

Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans

The New England journal of medicine, 2019-06, Vol.380 (25), p.2429-2439

2019

Volltextzugriff (PDF)

1 – 25 von 940

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(744)
Mit Volltextzugriff
(794)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(624)
Life Sciences & Biomedicine
(507)
Humans
(270)
Biological And Medical Sciences
(156)
Female
(146)
Male
(138)
Adult
(107)
Middle Aged
(98)
Plant Sciences
(97)
Technology
(87)
Medical Sciences
(83)
Fundamental And Applied Biological Sciences. Psychology
(74)
Aged
(69)
Social Sciences
(66)
Physical Sciences
(65)
Oncology
(64)
General & Internal Medicine
(57)
History
(55)
Medicine, General & Internal
(53)
Materials Science
(49)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors

Spontaneous Object Exploration in a Recessive Gene Knockout Model of Parkinson's Disease: Development and Progression of Object Recognition Memory Deficits in Male Pink1-/- Rats

Effect of educational intervention on medication reconciliation practice of hospital pharmacists in a developing country – A non-randomised controlled trial

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data

Traces and Memories of Slavery in the Atlantic World

The On- and Off-Ramps of Oncology Accelerated Approval

The Many Faces of Slavery : New Perspectives on Slave Ownership and Experiences in the Americas

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges

Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Review of Racial and Ethnic Representation of Participants Enrolled in Pediatric Clinical Trials of Oncology Drugs Conducted Through FDA Written Requests

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development

FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity

To Adjudicate or Not Adjudicate: That Is the Question

The Many Faces of Slavery

Re-Imagining the Guyanas

Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans

Suchergebnisse filtern